201 Haskins Way
South San Francisco, CA 94080
United States
650 695 0677
https://lyell.com
Secteur(s): Healthcare
Secteur d’activité: Biotechnology
Employés à temps plein: 224
Nom | Titre | Payer | Exercé | Année de naissance |
---|---|---|---|---|
Dr. Richard D. Klausner M.D. | Founder & Executive Chairman | 80k | S.O. | 1952 |
Dr. Lynn Seely M.D., Ph.D. | President, CEO & Director | 430,69k | S.O. | 1959 |
Mr. Charles W. Newton | Chief Financial Officer | 1,72M | S.O. | 1971 |
Mr. Stephen J. Hill | Chief Operating Officer | 1,04M | S.O. | 1970 |
Dr. Gary Lee Ph.D. | Chief Scientific Officer | 639,91k | S.O. | 1977 |
Ms. Elizabeth Homans | Consultant | 1,99M | S.O. | 1966 |
Prof. Stanley R. Riddell M.D. | Founder & Scientific Advisor | S.O. | S.O. | S.O. |
Dr. Crystal L. Mackall M.D. | Founder & Scientific Advisor | S.O. | S.O. | 1961 |
Nellie Dillery | Director of Accounting | S.O. | S.O. | S.O. |
Ms. Ellen Rose | Senior Vice President of Communications & Investor Relations | S.O. | S.O. | S.O. |
Lyell Immunopharma, Inc., a clinical-stage cell therapy company, develops T cell reprogramming technologies for patients with solid tumors. The company develops therapies using an ex vivo genetic reprogramming technologies, such as c Jun overexpression and NR4A3 gene knockout, to endow resistance to T cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi R to generate population of T cells with durable stemness, and Stim R, a proprietary synthetic cell mimetic. It is also developing LYL797, a genetically and epigenetically reprogrammed ROR1 chimeric antigen receptor (CAR) T cell product candidate that is in Phase 1 clinical trial for the treatment of various solid tumors; and LYL845, a novel epigenetically reprogrammed tumor-infiltrating lymphocytes product candidate, which is in Phase 1 clinical trial targeting multiple solid tumor indications. In addition, the company's preclinical product candidates include LYL119, a ROR1 CAR T-cell product for the treatment of enhanced cytotoxicity; and second generation TIL product. Lyell Immunopharma, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.
L’ISS Governance QualityScore de Lyell Immunopharma, Inc. en date du 1 avril 2024 est 8. Les scores principaux sont Audit : 3; Société : 7; Droits des actionnaires : 8; Compensation : 9.